WO2019066359A3 - 다파글리플로진 l-프롤린과 메트포르민을 포함하는 약제학적 복합제제 - Google Patents

다파글리플로진 l-프롤린과 메트포르민을 포함하는 약제학적 복합제제 Download PDF

Info

Publication number
WO2019066359A3
WO2019066359A3 PCT/KR2018/011004 KR2018011004W WO2019066359A3 WO 2019066359 A3 WO2019066359 A3 WO 2019066359A3 KR 2018011004 W KR2018011004 W KR 2018011004W WO 2019066359 A3 WO2019066359 A3 WO 2019066359A3
Authority
WO
WIPO (PCT)
Prior art keywords
dapagliflozin
metformin
proline
pharmaceutical formulation
combined pharmaceutical
Prior art date
Application number
PCT/KR2018/011004
Other languages
English (en)
French (fr)
Other versions
WO2019066359A2 (ko
Inventor
조정현
김형서
권택관
김용일
Original Assignee
한미약품 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020180079614A external-priority patent/KR102369679B1/ko
Application filed by 한미약품 주식회사 filed Critical 한미약품 주식회사
Priority to BR112020006395-9A priority Critical patent/BR112020006395A2/pt
Priority to MX2020002312A priority patent/MX2020002312A/es
Publication of WO2019066359A2 publication Critical patent/WO2019066359A2/ko
Publication of WO2019066359A3 publication Critical patent/WO2019066359A3/ko
Priority to PH12020500532A priority patent/PH12020500532A1/en
Priority to ZA2020/01892A priority patent/ZA202001892B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

본 발명은 다파글리플로진 L-프롤린과 메트포르민을 동시에 포함하는 복합 제제에 관한 것으로, 본 발명의 복합 제제는 보관 안정성 및 성상 안정성이 개선되고 우수한 용출률을 나타낼 뿐만 아니라 복약 편의성이 높아 장기 복용에 용이하다. 또한, 상기 복합 제제는 당뇨병, 당뇨병 관련 질환 또는 당뇨병성 합병증의 예방 또는 치료에 유용하게 사용될 수 있다.
PCT/KR2018/011004 2017-09-29 2018-09-18 다파글리플로진 l-프롤린과 메트포르민을 포함하는 약제학적 복합제제 WO2019066359A2 (ko)

Priority Applications (4)

Application Number Priority Date Filing Date Title
BR112020006395-9A BR112020006395A2 (pt) 2017-09-29 2018-09-18 formulação combinada e seu uso, método para preparar uma formulação combinada
MX2020002312A MX2020002312A (es) 2017-09-29 2018-09-18 Farmaceutica combinada que comprende dapagliflozina l-prolina y metformina.
PH12020500532A PH12020500532A1 (en) 2017-09-29 2020-03-13 Combined pharmaceutical formulation comprising dapagliflozin l-proline and metformin
ZA2020/01892A ZA202001892B (en) 2017-09-29 2020-03-24 Combined pharmaceutical formulation comprising dapagliflozin l-proline and metformin

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2017-0126878 2017-09-29
KR20170126878 2017-09-29
KR1020180079614A KR102369679B1 (ko) 2017-09-29 2018-07-09 다파글리플로진 l-프롤린과 메트포르민을 포함하는 약제학적 복합제제
KR10-2018-0079614 2018-07-09

Publications (2)

Publication Number Publication Date
WO2019066359A2 WO2019066359A2 (ko) 2019-04-04
WO2019066359A3 true WO2019066359A3 (ko) 2019-05-16

Family

ID=65901595

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/011004 WO2019066359A2 (ko) 2017-09-29 2018-09-18 다파글리플로진 l-프롤린과 메트포르민을 포함하는 약제학적 복합제제

Country Status (3)

Country Link
MX (1) MX2020002312A (ko)
WO (1) WO2019066359A2 (ko)
ZA (1) ZA202001892B (ko)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090023643A (ko) * 2006-06-28 2009-03-05 브리스톨-마이어스 스큅 컴퍼니 당뇨병 치료를 위한 ｓｇｌｔ2 억제제로서의, (1ｓ)-1,5-안히드로-1-ｃ-(3-((페닐)메틸)페닐)-ｄ-글루시톨 유도체와 아미노산의 결정질 용매화물 및 복합체
KR20140131950A (ko) * 2012-03-07 2014-11-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 및 ｄｄｐ―４ 억제제 또는 ｓｇｌｔ―２ 억제제를 포함하는 약제학적 조성물
KR101526825B1 (ko) * 2014-12-23 2015-06-08 주식회사 한독 당뇨병 치료용 약제학적 조성물
US20150238421A1 (en) * 2009-11-13 2015-08-27 Astrazeneca Ab Bilayer Tablet Formulations
WO2017114227A1 (zh) * 2015-12-30 2017-07-06 深圳翰宇药业股份有限公司 一种复方达格列净二甲双胍缓释片及其制备方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090023643A (ko) * 2006-06-28 2009-03-05 브리스톨-마이어스 스큅 컴퍼니 당뇨병 치료를 위한 ｓｇｌｔ2 억제제로서의, (1ｓ)-1,5-안히드로-1-ｃ-(3-((페닐)메틸)페닐)-ｄ-글루시톨 유도체와 아미노산의 결정질 용매화물 및 복합체
US20150238421A1 (en) * 2009-11-13 2015-08-27 Astrazeneca Ab Bilayer Tablet Formulations
KR20140131950A (ko) * 2012-03-07 2014-11-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 및 ｄｄｐ―４ 억제제 또는 ｓｇｌｔ―２ 억제제를 포함하는 약제학적 조성물
KR101526825B1 (ko) * 2014-12-23 2015-06-08 주식회사 한독 당뇨병 치료용 약제학적 조성물
WO2017114227A1 (zh) * 2015-12-30 2017-07-06 深圳翰宇药业股份有限公司 一种复方达格列净二甲双胍缓释片及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DENG, J. -H. %: "Dapagliflozin-citric acid cocrystal showing better solid state properties than Dapagliflozin", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 13 April 2017 (2017-04-13), pages 255 - 261, XP085093809, DOI: doi:10.1016/j.ejps.2017.04.008 *

Also Published As

Publication number Publication date
MX2020002312A (es) 2020-09-17
WO2019066359A2 (ko) 2019-04-04
ZA202001892B (en) 2023-06-28

Similar Documents

Publication Publication Date Title
EP3804714A4 (en) PHARMACEUTICAL COMBINATION AND COMPOSITION AND COMBINATION PREPARATION OF GLUCOKINASE ACTIVATOR AND HYPOGLYCEMIC BIGUANIDE DRUG, AND METHOD OF MANUFACTURE AND USE THEREOF
PH12017501222A1 (en) Glucagon derivatives with improved stability
MY159865A (en) Aqueous insulin preparations containing methionine
WO2015038533A3 (en) Sodium channel modulators for the treatment of pain and diabetes
WO2015128403A3 (en) An a22k, desb27, b29r, des b30, at epsilon position of lysine 22 acylated human insulin analogue
PH12019502655A1 (en) Acylated insulin compound
MX336657B (es) Prevencion de hipoglucemia en pacientes con diabetes sacarina de tipo 2.
MX347372B (es) Uso de metformina en combinacion con un activador de glucoquinasa y composiciones que comprenden metformina y un activador de glucoquinasa.
MX2018002223A (es) Derivados de insulina novedosos y usos medicos de los mismos.
WO2018097570A3 (ko) 다파글리플로진 l-프롤린을 포함하는 약제학적 제제
JP2017502074A5 (ko)
JOP20210201A1 (ar) مركب لخفض جلوكوز الدم
WO2018005794A3 (en) Novel non-systemic tgr5 agonists
AU2013330679A8 (en) Combination drug comprising gemigliptin and metformin, and method for the preparation thereof
CR20220641A (es) Compuestos de insulina acilada de acción temporal prolongada
PH12018500817A1 (en) Pharmaceutical composition comprising metformin and lobeglitazone
PH12020550050A1 (en) Novel acylated insulin analogues and uses thereof
PH12020500532A1 (en) Combined pharmaceutical formulation comprising dapagliflozin l-proline and metformin
WO2019066359A3 (ko) 다파글리플로진 l-프롤린과 메트포르민을 포함하는 약제학적 복합제제
AU2017258649A1 (en) Covalent BTK inhibitors and uses thereof
BRPI0815280A2 (pt) medicamento que compreende uma formulação líquida aquosa de g-csf, receptáculo para a administração de medicamentos líquidos, seringa ou ampola, kit para a administração parenteral de g-csf
MX2018011293A (es) Composicion farmaceutica de liberacion prolongada que comprende cisteamina o sal de la misma.
CR20220620A (es) Composición farmacéutica acuosa de levilimab y su uso
WO2016126026A3 (ko) 당뇨병 치료 조성물 및 이의 용도
MXPA06000760A (es) Composicion farmaceutica estable de carisoprodol y meloxicam.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18860024

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112020006395

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112020006395

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20200330

122 Ep: pct application non-entry in european phase

Ref document number: 18860024

Country of ref document: EP

Kind code of ref document: A2